<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;utm_medium=rss&amp;utm_campaign=pub med-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 28 日星期一 16:10:05 +0000</lastbuilddate><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>一级预防中他汀类药物管理的建议：国际风险评分之间的差异</title><link/>https://pubmed.ncbi.nlm.nih.gov/37638490/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>结论：即使在相同的患者中，风险算法在风险估计、他汀类药物治疗建议和辅助测试的使用方面也存在很大差异。这些结果凸显了目前使用的基于风险的方法在一级预防中解决脂质特异性风险的局限性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad539。doi：10.1093/eurheartj/ehad539。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：他汀类药物在一级预防中的建议取决于风险算法。此外，对于中等风险，提倡使用风险增强剂和去增强剂来帮助患者做出需要他汀类药物的决定或考虑风险增强剂和去增强剂。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：模拟人群（n = 7680），男女相等，吸烟/不吸烟，年龄 45-70 岁，总胆固醇 3.5-7.0 mmol/L，高密度脂蛋白胆固醇 0.6-2.2 mmol/L，收缩压血压 100-170 mmHg 进行评估。使用弗雷明汉风险评分 (FRS)、合并队列方程 (PCE)、四个版本的系统性冠状动脉风险评估 2 (SCORE2) 和多版本来确定高风险、中风险和低风险。动脉粥样硬化种族研究 (MESA) 算法（0-1000 Agatston 单位）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：三个风险级别的一致性从 19% 到 85% 不等。根据所应用的算法，即使风险因素负担相同，两种性别也可能被认为具有低、中或高风险。只有 SCORE2（高）排除 MESA，中度风险的比例为 25%（SCORE2，极高风险区域）、32%（FRS）、39%（PCE）和 45%（SCORE2，低风险区域）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：即使在相同的患者中，风险算法在风险估计、他汀类药物治疗建议和辅助测试的使用方面也存在很大差异。这些结果凸显了目前使用的基于风险的方法在一级预防中解决脂质特异性风险的局限性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37638490/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37638490</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad539>10.1093/eurheartj/ehad539</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37638490</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>英国约翰·曼奇尼</dc:creator><dc:creator>阿诺·良本</dc:creator><dc:creator>杨尤妮丝</dc:creator><dc:creator>利亚姆·R·布鲁纳姆</dc:creator><dc:creator>罗伯特·A·黑格勒</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>一级预防中他汀类药物管理的建议：国际风险评分之间的差异</dc:title><dc:identifier>下午：37638490</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad539</dc:identifier></item><item><title> FAM3D 在心肌缺血再灌注损伤中的心脏保护和抗炎作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37638415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 28 日。doi：10.1161/CIRCRESAHA.123.322640。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37638415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37638415</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322640>10.1161/CIRCRESAHA.123.322640</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37638415</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>詹姆斯·李</dc:creator><dc:creator>——丽贝卡·弗里曼</dc:creator><dc:creator>卢康山</dc:creator><dc:creator>玛格丽特·莱昂斯</dc:creator><dc:creator>肖春阳</dc:creator><dc:creator>丹尼尔·兹洛托夫</dc:creator><dc:creator>阿什什·耶里</dc:creator><dc:creator>李浩波</dc:creator><dc:creator>贾斯汀·格拉</dc:creator><dc:creator>J·萨瓦拉·古塞</dc:creator><dc:creator>亚历山德拉·库兹涅佐夫</dc:creator><dc:creator>尼古拉斯·休斯蒂斯</dc:creator><dc:creator>贾森·罗</dc:creator><dc:creator>费德里科·达米兰</dc:creator><dc:creator>刘晓军</dc:creator><dc:creator>——迈克尔·西尔弗曼</dc:creator><dc:creator>邝伟文</dc:creator><dc:creator>索米亚·达斯</dc:creator><dc:creator>安东尼·罗森茨威格</dc:creator><dc:date>2023-08-28</dc:date><dc:source>流通研究</dc:source><dc:title>FAM3D 在心肌缺血再灌注损伤中的心脏保护和抗炎作用</dc:title><dc:identifier>下午：37638415</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322640</dc:identifier></item><item><title>皮肤病变、体重减轻和室性心动过速：连接点以诊断多系统结节病</title><link/>https://pubmed.ncbi.nlm.nih.gov/37638411/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad501。doi：10.1093/eurheartj/ehad501。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37638411/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37638411</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad501>10.1093/eurheartj/ehad501</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37638411</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>埃丝特·帕皮奥尔</dc:creator><dc:creator>巴勃罗·帕斯特更多</dc:creator><dc:creator>伊娃·普奥</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>皮肤病变、体重减轻和室性心动过速：连接点以诊断多系统结节病</dc:title><dc:identifier>下午：37638411</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad501</dc:identifier></item><item><title> 3 维双曲面电路中传导块固定线划分的人体室性心动过速的识别</title><link/>https://pubmed.ncbi.nlm.nih.gov/37638389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>结论：大多数 VT 回路边界可以被识别为窦性心律期间内在或起搏激活的固定 LOB。在疤痕基质内起搏时分析激活是一种新技术，可以揭示隐藏的 LOB，以前被解释为具有功能性。从心肌表面的角度来看，LOB 经常与壁内传导相关，支持 3D 双曲面 VT 回路结构的存在。导管消融可能... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 28 日。doi：10.1161/CIRCULATIONAHA.123.065525。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：折返性室性心动过速 (VT) 的回路边界历来被概念化为二维 (2D) 结构，其固定或功能性质尚未解决。本研究旨在检查局部传导线阻滞 (LOB) 之间的相关性基线节律期间的证据，具有横向峡部边界，在 3 维上将 VT 峡部限制为双曲面结构。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：来自 3 个中心（42% 非缺血性心肌病）的 106 名患者因疤痕基线 VT 接受导管消融术，总共 175 个 VT 激活图与节律期间的等时迟激活图相关。明显的 LOB 由减速区定义。基线节律期间具有分裂电位（≥20 ms 等电段）。减速区内起搏（≥600 ms）的新应用被实施，以揭示基线节律期间不明显的隐藏 LOB。基线节律或起搏期间识别的 LOB 与VT 期间的峡部边界。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在基线节律期间分析的 202 个减速区中，47% 存在明显的 LOB。当在 38 个没有明显 LOB 的减速区中进行差异起搏时，84% 的潜在隐藏 LOB 暴露。在 152 个 VT 激活图（2D）中， =53，3 维 [3D]=99)，69% 的横向边界与 2D 激活模式中的 LOB 共定位，3D VT 期间的深度边界与 79% 的 LOB 共定位。 =28），边界总是在 2D 和 3D 中充当横向边界。总体而言，74% 的峡部边界在基线节律或差异起搏期间可识别为固定 LOB。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：大多数 VT 回路边界可以被识别为窦性心律期间内在或起搏激活的固定 LOB。在疤痕基质内起搏时分析激活是一种新技术，可以揭示隐藏的 LOB，以前被解释为具有功能性。从心肌表面的角度来看，LOB 经常与壁内传导相关，支持 3D 双曲面 VT 回路结构的存在。导管消融可以简化为在窦性心律期间针对已识别 LOB 周围的两侧。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37638389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37638389</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065525>10.1161/CIRCULATIONAHA.123.065525</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37638389</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>西村拓郎</dc:creator><dc:creator>——内森·沙茨</dc:creator><dc:creator>彼得·韦斯</dc:creator><dc:creator>迈克尔·扎瓦内</dc:creator><dc:creator>荣白</dc:creator><dc:creator>——安德鲁·D·比瑟</dc:creator><dc:creator>Gaurav A Upadhyay更多</dc:creator><dc:creator>扎伊德·阿齐兹</dc:creator><dc:creator>赫马尔·M·纳亚克</dc:creator><dc:creator>达利斯·Y·沙茨</dc:creator><dc:creator>宫崎信介</dc:creator><dc:creator>戈雅正彦</dc:creator><dc:creator>笹野哲夫</dc:creator><dc:creator>苏维柏</dc:creator><dc:creator>——迈克尔·雷曼</dc:creator><dc:creator>童罗德里克</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>3 维双曲面电路中传导块固定线划分的人体室性心动过速的识别</dc:title><dc:identifier>下午：37638389</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065525</dc:identifier></item><item><title>达格列净治疗心力衰竭且估计肾小球滤过率恶化至 &lt;25ml/min/1.73m&lt;sup>;2&lt;/sup>; 的患者</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>结论：肾功能恶化低于 eGFR 25ml/min/1.73m² 的患者心血管结局风险升高，但似乎可以从继续使用达格列净中获益，且治疗组之间的安全性结果没有过高。肾功能。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 8 月 23 日：S0735-1097(23)06532-4。doi：10.1016/j.jacc.2023.08.026。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：SGLT-2 抑制剂是心力衰竭 (HF) 治疗指南推荐的药物。虽然即使在合并 CKD 的患者中也可以开始这些治疗，但随着时间的推移，一些患者可能会面临肾功能恶化的情况。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：检查当 eGFR 低于起始阈值时持续使用 SGLT-2 抑制剂治疗心力衰竭的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在 DAPA-HF 和 DELIVER 的参与者水平汇总分析中，通过时间更新的 Cox 比例风险模型评估 eGFR 恶化低于 25 ml/min/1.73m <sup>2</sup> 、疗效和安全性结果与达格列净治疗之间的关联。 。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 11,007 名患者中，347 名 (3.2%) 患者在随访中至少有一次 eGFR 恶化至&lt;25ml/min/1.73m <sup>2。</sup>这些患者的主要复合结局风险较高（HR 1.87；95%） CI：1.48-2.35，p&lt;0.001）。与安慰剂相比，达格列净的主要结局风险较低，无论是接受治疗（HR 0.53；95% CI：0.33-0.83）还是未接受治疗（HR 0.78；95）的患者。 % CI: 0.72-0.86) 在 eGFR&lt;25ml/min/ <sup>1.73m2</sup>以下经历肾功能恶化（P<sub>相互作用</sub>=0.17）。eGFR&lt;25ml/min/1.73 恶化的患者中，安全性结果（包括停药）的风险较高<sup>m2</sup> ；然而，治疗组之间的比率仍然相似，包括那些仍然服用研究药物的患者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：肾功能恶化低于 eGFR 25ml/min/1.73m <sup>2</sup>的患者心血管结局风险较高，但似乎可以从继续使用达格列净中获益，且治疗组之间的安全性结果没有过高。肾功能恶化。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634707</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.026>10.1016/j.jacc.2023.08.026</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634707</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>萨菲亚·查图尔</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:creator>——布莱恩·L·克拉吉特</dc:creator><dc:creator>芬尼安·R·麦考斯兰</dc:creator><dc:creator>Akshay S Desai更多</dc:creator><dc:creator>帕迪普·S·琼德</dc:creator><dc:creator>鲁道夫·德波尔</dc:creator><dc:creator>——阿德里安·F·埃尔南德斯</dc:creator><dc:creator>西尔维奥·因祖奇</dc:creator><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>费利佩·马丁内斯</dc:creator><dc:creator>桑吉夫·J·沙阿</dc:creator><dc:creator>马克·S·萨巴廷</dc:creator><dc:creator>拉斯·科伯</dc:creator><dc:creator>彼得·波尼科夫斯基</dc:creator><dc:creator>贝拉·默克利</dc:creator><dc:creator>马格努斯·彼得森</dc:creator><dc:creator>安娜·玛丽亚·朗基尔德</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:date>2023-08-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>达格列净治疗心力衰竭且估计肾小球滤过率恶化至 &lt;25ml/min/1.73m&lt;sup>;2&lt;/sup>; 的患者</dc:title><dc:identifier>下午：37634707</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.026</dc:identifier></item><item><title>冠状动脉血流能力和血运重建后的生存预测：生理学基础和临床意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>结论：与 CFC 严重程度未进行血运重建相比，首次和重复血运重建后 CFC 严重减少，相关的观察到的生存概率有所改善。非严重 CFC 没有显示任何益处。血运重建后观察到的实际生存概率和虚拟假设生存概率之间的不一致表明存在残余 CAD 或失败血运重建。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad579。doi：10.1093/eurheartj/ehad579。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：冠状动脉血流能力 (CFC) 与实际血运重建前后个体患者观察到的 10 年生存概率相关，以便与虚拟假设的理想完全血运重建进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用 Rb-82 正电子发射断层扫描 (PET) 绘制动脉特定尺寸的 CFC 图，对 6979 名冠状动脉疾病 (CAD) 受试者的应激性心肌灌注 (mL/min/g) 和每像素冠状动脉血流储备 (CFR) 进行量化-严重异常表示为左心室百分比 (%LV)，并进行前瞻性随访，将每十年的生存概率定义为 1.0 的分数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：6979 名受试者的 CFC 严重减少，预测生存概率较低，与同等严重程度的未进行血运重建相比，血运重建后生存概率提高了 42% (P=0.0015)。对于 283 组术前和术后 PET 对，与区域 CFC 相关的区域性 CFC 严重减少血运重建后生存概率存在异质性改善（P&lt;0.001），搭桥手术后生存概率比经皮冠状动脉介入治疗后改善更大（P&lt;0.001），但正常化率仅为 5.7%；与严重 CFC 相比，非严重基线 CFC 或生存概率没有改善（P =0.00001).观察到的CFC=实际血运重建后的相关生存概率低于由于残余CAD或血运重建失败而导致的虚拟理想假设完全血运重建后生存概率(P&lt;0.001)，与性别或微血管功能障碍无关。2552年后CFC严重减少-与不重复手术相比，与低生存概率相关的血运重建受试者在重复血运重建后也得到改善（P=0.025）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与 CFC 严重程度未进行血运重建相比，首次和重复血运重建后 CFC 严重减少，相关的观察到的生存概率有所改善。非严重 CFC 没有显示任何益处。血运重建后观察到的实际生存概率和虚拟假设生存概率之间的不一致表明存在残余 CAD 或失败血运重建。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634192</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad579>10.1093/eurheartj/ehad579</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634192</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator> K·兰斯·古尔德</dc:creator><dc:creator>尼尔斯·P·约翰逊</dc:creator><dc:creator>阿曼达·E·罗比</dc:creator><dc:creator>灵碧</dc:creator><dc:creator>达奈·基孔万</dc:creator><dc:creator>莫妮卡·B·帕特尔</dc:creator><dc:creator>阮东</dc:creator><dc:creator>理查德·柯基德</dc:creator><dc:creator>玛丽·海妮</dc:creator><dc:creator>萨尔曼·阿兰</dc:creator><dc:creator>康斯坦丁诺斯·查里塔基斯</dc:creator><dc:creator>阿比吉特·多布尔</dc:creator><dc:creator>——理查德·斯莫林</dc:creator><dc:creator>安吉洛·纳辛贝内</dc:creator><dc:creator>Marwan Jumean更多</dc:creator><dc:creator>萨钦·库马尔</dc:creator><dc:creator>比斯瓦吉特·卡尔</dc:creator><dc:creator>斯特凡诺·斯德林戈拉</dc:creator><dc:creator>安东尼·埃斯特雷拉</dc:creator><dc:creator>伊戈尔·格雷戈里姆</dc:creator><dc:creator>赖德建</dc:creator><dc:creator>李若莎</dc:creator><dc:creator>大卫·麦克弗森</dc:creator><dc:creator>贾加特·纳鲁拉</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>冠状动脉血流能力和血运重建后的生存预测：生理学基础和临床意义</dc:title><dc:identifier>下午：37634192</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad579</dc:identifier></item><item><title>心脏磁共振成像与计算机断层扫描指导经导管主动脉瓣置换术 (TAVR-CMR)：一项随机、开放标签、非劣效性试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>背景：计算机断层扫描（CT）被推荐用于指导经导管主动脉瓣置换术（TAVR）。然而，由于相当大比例的 TAVR 候选者患有慢性肾脏病（CKD），碘造影剂的使用受到限制。CMR）是一种比较 CMR 与 CT 引导 TAVR 有效性的有希望的替代方案，但缺乏随机数据。方法：一项研究者发起的、前瞻性的、随机的、开放标签的、非劣效性试验…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 27 日。doi：10.1161/CIRCULATIONAHA.123.066498。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>计算机断层扫描（CT）被推荐用于指导经导管主动脉瓣置换术（TAVR）。然而，由于相当大比例的 TAVR 候选者患有慢性肾脏病（CKD），碘造影剂的使用受到限制。CMR）是一种<b>方法：</b>在两个奥地利心脏中心进行了一项研究者发起的前瞻性、随机、开放标签、非劣效性试验，对接受 TAVR 评估的患者进行了比较。根据纳入（严重症状性主动脉瓣狭窄）和排除标准（CMR、CT 或 TAVR 禁忌、预期寿命 &lt; 1 年、CKD 4 或 5）被随机（1:1）接受 CMR 或 CT 引导主要结局是根据瓣膜学术研究联盟 2 对出院时植入成功的定义进行定义，包括无手术死亡率、单个人工瓣膜的正确定位以及适当的人工瓣膜性能。使用混合方法评估非劣效性基于 9% 绝对风险差异裕度的改良意向治疗 (mITT)/按方案 (PP) 方法。<b>结果：</b> 2017 年 9 月 11 日至 2022 年 12 月 16 日期间，380 名 TAVR 候选者被随机分配至 CMR -引导（191例患者）或CT引导（189例患者）TAVR计划。其中，CMR引导组中的138例患者（72.3%）和CT引导组中的129例患者（68.3%）最终接受了TAVR（mITT）在这 267 名患者中，有 19 名患者出现方案偏差，从而形成 248 名患者的 PP 队列（n=121 例 CMR 引导，n=127 例 CT 引导）。CMR 组中有 129 名患者 (93.5%) 实现了这一目标，在 CT 组的 117 名患者 (90.7%) 中（组间差异为 2.8%；90% 置信区间 [CI]：-2.7 至 8.2%；p&lt;0.01 在 PP 队列 (n=248) 中，组间差异为 2.0%（90% CI：-3.8 至 7.8%；非劣效性 p&lt;0.01）。<b>结论：</b>就装置植入成功率而言，CMR 引导的 TAVR 并不劣于 CT 引导的 TAVR。因此，CMR 可以被视为 TAVR 规划的替代方案。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634187</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066498>10.1161/CIRCULATIONAHA.123.066498</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634187</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>马丁·雷德尔</dc:creator><dc:creator>伊万·莱希纳</dc:creator><dc:creator>玛格达莱娜·霍尔兹克内西特</dc:creator><dc:creator>克里斯蒂娜·蒂勒</dc:creator><dc:creator>普里西拉·芬克</dc:creator><dc:creator>弗里茨·奥伯霍伦泽</dc:creator><dc:creator>塞巴斯蒂安·冯·德·埃姆德</dc:creator><dc:creator>马蒂亚斯·帕明格</dc:creator><dc:creator>菲利克斯·特罗格</dc:creator><dc:creator>克里斯蒂安·克莱姆瑟</dc:creator><dc:creator>伊丽莎白·拉斯尼格</dc:creator><dc:creator>——凯瑟琳·丹宁格</dc:creator><dc:creator>罗纳德·宾德</dc:creator><dc:creator>汉诺·乌尔默</dc:creator><dc:creator>克里斯托夫·布伦纳</dc:creator><dc:creator>格特·克鲁格</dc:creator><dc:creator>阿克塞尔·鲍尔</dc:creator><dc:creator>伯恩哈德·梅茨勒</dc:creator><dc:creator>艾格尼丝·迈尔</dc:creator><dc:creator>塞巴斯蒂安·约翰内斯·赖因斯塔德勒</dc:creator><dc:date>2023-08-27</dc:date><dc:source>循环</dc:source><dc:title>心脏磁共振成像与计算机断层扫描指导经导管主动脉瓣置换术 (TAVR-CMR)：一项随机、开放标签、非劣效性试验</dc:title><dc:identifier>下午：37634187</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066498</dc:identifier></item><item><title>瞬时无波比率与血流储备分数相比：重新考虑当前建议的时间</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad574。doi：10.1093/eurheartj/ehad574。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634167</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad574>10.1093/eurheartj/ehad574</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634167</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>米尔瓦特·阿拉斯纳格</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>瞬时无波比率与血流储备分数相比：重新考虑当前建议的时间</dc:title><dc:identifier>下午：37634167</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad574</dc:identifier></item><item><title>与血流储备分数相比，瞬时无波比指导的冠状动脉血运重建：DEFINE-FLAIR 和 iFR-SWEDEHEART 试验中 5 年死亡率的汇总</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad552。doi：10.1093/eurheartj/ehad552。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634165</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad552>10.1093/eurheartj/ehad552</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634165</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>科林·贝瑞</dc:creator><dc:creator>约翰·D·麦克卢尔</dc:creator><dc:creator>基思·奥尔德罗伊德</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>与血流储备分数相比，瞬时无波比指导的冠状动脉血运重建：DEFINE-FLAIR 和 iFR-SWEDEHEART 试验中 5 年死亡率的汇总</dc:title><dc:identifier>下午：37634165</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad552</dc:identifier></item><item><title>慢性冠状动脉综合征中的新发房颤：CLARIFY 登记处</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>结论：在 CCS 患者中，NOAF 很常见，并且与较差的预后密切相关。更强化的预防措施和更系统的 AF 筛查是否会改善该人群的预后值得进一步研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad556。doi：10.1093/eurheartj/ehad556。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：关于慢性冠状动脉综合征（CCS）患者新发心房颤动（NOAF）的数据很少。本研究旨在描述 CCS 患者中 NOAF 的发生率、预测因素及其对心血管结局的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用来自国际（45 个国家）CLARIFY 登记处（稳定性冠状动脉疾病患者的前瞻性观察性纵向登记处）的数据。在 29,001 名基线时未曾报告过 AF 的 CCS 门诊患者中，诊断出至少有 1 次 AF/扑动发作的患者将 5 年随访期间的患者与整个研究期间窦性心律的患者进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：NOAF 的发生率为每 100 患者年 1.12 [95% 置信区间 (CI) 1.06-1.18]（5 年累积发生率：5.0%）。NOAF 的独立预测因素是年龄增加、体重指数增加、估计肾小球滤过率低、白人种族、酒精摄入量和左心室射血分数低，而高甘油三酯与较低的发病率相关。NOAF 与不良结果风险大幅增加相关，调整后的风险比为 2.01（95%） ). 心血管死亡、非致命性心肌梗塞或非致命性中风的复合物 CI 1.61-2.52)，心血管死亡 2.61 (95% CI 2.04-3.34)，非致命性死亡 1.64 (95% CI 1.07-2.50)致命性心肌梗死、全因死亡为 2.27 (95% CI 1.85-2.78)、因心力衰竭住院为 8.44 (95% CI 7.05-10.10)、大出血为 4.46 (95% CI 2.85-6.99)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在 CCS 患者中，NOAF 很常见，并且与较差的预后密切相关。更强化的预防措施和更系统的 AF 筛查是否会改善该人群的预后值得进一步研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634147</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad556>10.1093/eurheartj/ehad556</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634147</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>亚历山大·戈蒂埃</dc:creator><dc:creator>——法比安·皮卡德</dc:creator><dc:creator>——格雷戈里·杜克罗克</dc:creator><dc:creator>耶迪德·埃尔贝兹</dc:creator><dc:creator>金·M·福克斯</dc:creator><dc:creator>罗伯托·法拉利</dc:creator><dc:creator>——伊恩·福特</dc:creator><dc:creator>让-克洛德·塔迪夫</dc:creator><dc:creator>Michal Tendera更多</dc:creator><dc:creator>菲利普·加布里埃尔·施泰格</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>慢性冠状动脉综合征中的新发房颤：CLARIFY 登记处</dc:title><dc:identifier>下午：37634147</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad556</dc:identifier></item><item><title>与血流储备分数相比，当冠状动脉血运重建由无波比率指导时，五年主要瞬时心血管事件会增加：iFR-SWEDEHEART 和 DEFINE-FLAIR 试验的汇总分析。</title><link/> https://pubmed.ncbi.nlm.nih.gov/37634144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>结论：与 FFR 相比，iFR 指导下的血运重建的五年全因死亡率和 MACE 发生率有所增加。两组的非计划血运重建和 MI 发生率相同。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad582。doi：10.1093/eurheartj/ehad582。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：指南建议以缺血证据为指导对心外膜中间动脉狭窄进行血运重建。同样推荐血流储备分数 (FFR) 和瞬时无波比 (iFR)。两项主要随机试验的单独 5 年结果比较iFR 引导的血运重建的 FFR 表明 iFR 引导的血运重建后全因死亡率增加。本研究的目的是对 iFR-SWEDEHEART (NCT02166736) 和 DEFINE-FLAIR (NCT02166736) 的 5 年结果数据进行研究级荟萃分析。 NCT02053038）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：分析了主要不良心血管事件 (MACE) 及其各个组成部分 [全因死亡、心肌梗死 (MI) 和计划外血运重建] 的综合情况。原始 Kaplan-Meier 估计值、风险人数和事件数提取于使用 ipdfc 软件包（Stata 版本 18，StataCorp College Station，TX USA）进行 5 年跟踪和分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共分别有 2,254 名和 2,257 名患者进行了 iFR 和 FFR 指导的血运重建。iFR 组 [n = 1,128 (50.0 %)] 与 FFR 组 [n = 1021] 相比，血运重建更常被推迟。 (45.2%)；p=0.001]。在 iFR 指导组中，死亡、MACE、非计划血运重建和 MI 的人数分别为 188 例 (8.3%)、484 例 (21.5%)、235 例 (10.4%) 和 123 例。 5.5%) vs. FFR 组中的 143 (6.3%)、420 ​​(18.6%)、241 (10.7%) 和 123 (5.4%)。MACE 的风险比 [95% 置信区间 (CI)] 估计值为1.18 [1.035; 1.34]，全因死亡率 1.34 [1.08; 1.67]，计划外血运重建 0.99 [0.83; 1.19]，MI 1.02 [0.80; 1.32]。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与 FFR 相比，iFR 指导下的血运重建的五年全因死亡率和 MACE 发生率有所增加。两组的非计划血运重建和 MI 发生率相同。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634144</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad582>10.1093/eurheartj/ehad582</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634144</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>阿什坎·埃夫特卡里</dc:creator><dc:creator>埃米尔·尼尔森·霍尔克</dc:creator><dc:creator>杰尔默·韦斯特拉</dc:creator><dc:creator>尼尔斯·图·奥尔森</dc:creator><dc:creator>尼尔斯·亨利克·布鲁恩</dc:creator><dc:creator>莉塞特·奥克斯·詹森</dc:creator><dc:creator>托马斯·恩斯特罗姆</dc:creator><dc:creator>埃瓦尔德·霍伊·克里斯蒂安森</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>与血流储备分数相比，当冠状动脉血运重建由无波比率指导时，五年主要瞬时心血管事件会增加：iFR-SWEDEHEART 和 DEFINE-FLAIR 试验的汇总分析。</dc:title><dc:identifier>下午：37634144</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad582</dc:identifier></item><item><title>危及肢体的严重缺血和微血管转化：临床意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>结论：这些发现描述了 CLTI 肌肉中微血管系统的渐进性、缺氧驱动的转变，这在病理上改变了血流动力学，并在低动脉驱动压下加剧了组织损伤。缺氧驱动的毛细血管扩张对于 CLTI 结果非常重要，因此应该进一步开发 CLTI 的诊断和治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 27 日：ehad562。doi：10.1093/eurheartj/ehad562。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：严重肢体威胁性缺血（CLTI）的临床治疗重点是预防和治疗动脉粥样硬化性动脉闭塞。微血管病理学在疾病进展中的作用仍然很大程度上未明确，更重要的是尚未用于治疗。一项探索性研究是表征微血管系统在 CLTI 病理学中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用 CLTI 患者 (n=50) 的临床高分辨率成像和来自 CLTI 截肢的肌肉样本 (n=40) 分别在静息肌肉血流和微血管结构水平上描述 CLTI 的微血管病理学。慢性、低动脉驱动压力模拟兔缺血模型（n=24）与腺病毒血管内皮生长因子 A 基因转移一起用于研究微血管改变对肌肉结果的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：CLTI肌肉静息时微血管血流并未减少，但毛细血管通过时间缩短（P&lt;0.01）。CLTI肌肉微血管还表现出毛细血管扩张（P&lt;0.001），并随着肌纤维萎缩恶化和毛细血管与肌纤维分离而进一步动脉化。此外，在慢性缺血的兔子和健康、正常的兔子肌肉中，CLTI 样毛细血管转化会恶化小腿肌肉的力量产生（P&lt;0.05）和组织结果（P&lt;0.01）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现描述了 CLTI 肌肉中微血管系统的渐进性、缺氧驱动的转变，这在病理上改变了血流动力学，并在低动脉驱动压下加剧了组织损伤。缺氧驱动的毛细血管扩张对于 CLTI 结果非常重要，因此应该进一步开发 CLTI 的诊断和治疗。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37634134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634134</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad562>10.1093/eurheartj/ehad562</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37634134</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator>桑特里·塔尔瓦宁</dc:creator><dc:creator>加林娜·沃斯</dc:creator><dc:creator>格蕾塔·尤索拉</dc:creator><dc:creator>奥利·豪特罗</dc:creator><dc:creator>卡里·卡利奥科斯基</dc:creator><dc:creator>塔尼娅·斯约罗斯</dc:creator><dc:creator>维科·尼库莱宁</dc:creator><dc:creator>朱尼·塔维赛宁</dc:creator><dc:creator>雅科·海托宁</dc:creator><dc:creator>克里斯特·弗里莫迪格</dc:creator><dc:creator>克里斯塔·哈波宁</dc:creator><dc:creator>托马斯·塞兰德</dc:creator><dc:creator>托米·莱蒂宁</dc:creator><dc:creator>哈里·H·哈科维尔塔</dc:creator><dc:creator>尤哈尼·克努蒂</dc:creator><dc:creator>尼海·拉哈姆·卡拉姆</dc:creator><dc:creator>尤哈·哈蒂凯宁</dc:creator><dc:creator>基莫·马基宁</dc:creator><dc:creator>塞波·伊拉·赫图阿拉</dc:creator><dc:creator>佩特拉·科皮萨洛</dc:creator><dc:date>2023-08-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>危及肢体的严重缺血和微血管转化：临床意义</dc:title><dc:identifier>下午：37634134</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad562</dc:identifier></item><item><title>体弱老年房颤患者从维生素 K 拮抗剂改用非维生素 K 拮抗剂口服抗凝剂的安全性：FRAIL-AF 随机对照试验的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37634130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230828121004&amp;v=2.17.9.post6+86293ac<description>背景：使用维生素 K 拮抗剂 (VKA) 治疗的虚弱心房颤动 (AF) 患者是否应改用非维生素 K 口服抗凝剂 (NOAC) 尚不明确。方法：我们进行了一项务实、多中心、开放标签、随机对照优效性试验。患有虚弱的老年 AF 患者（年龄≥75 岁且格罗宁根虚弱指标 (GFI) 评分≥3）被随机分配从 INR 指导的 VKA 治疗转为 NOAC 或继续 VKA 治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 27 日。doi：10.1161/CIRCULATIONAHA.123.066485。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> There is ambiguity whether frail patients with atrial fibrillation (AF) managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC). <b>Methods:</b> We conducted a pragmatic, multicenter, open-label, randomized controlled superiority trial. Older AF patients living with frailty (age ≥75 years plus a Groningen Frailty Indicator (GFI) score ≥3) were randomized to switch from INR-guided VKA treatment to a NOAC or to continued VKA treatment. Patients with a glomerular filtration rate &lt;30 mL/min/1.73 m <sup>2</sup> or with valvular AF were excluded. Follow-up was 12 months. The cause-specific hazard ratio (HR) was calculated for occurrence of the primary outcome which was a major or clinically relevant non-major bleeding complication, whichever came first, accounting for death as a competing risk. Analyses followed the intention-to-treat principle. Secondary outcomes included thromboembolic events. <b>Results:</b> Between January 2018 and June 2022, a total of 2,621 patients were screened for eligibility and 1,330 patients were randomized (mean age 83 years, median GFI 4). After randomization 6 patients in the switch to NOAC arm and 1 patient in the continue with VKA arm were excluded due to the presence of exclusion criteria, leaving 662 patients switched from a VKA to a NOAC and 661 patients continued VKAs in the intention-to-treat population. After 163 primary outcome events (101 in the switch arm, 62 in the continue arm), the trial was stopped for futility according to a prespecified futility analysis. The HR for our primary outcome was 1.69 (95% CI 1.23-2.32). The HR for thromboembolic events was 1.26 (95% CI 0.60 to 2.61). <b>Conclusions:</b> Switching INR-guided VKA treatment to a NOAC in frail older patients with AF was associated with more bleeding complications compared to continuing VKA treatment, without an associated reduction in thromboembolic complications.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37634130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634130</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066485>10.1161/CIRCULATIONAHA.123.066485</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37634130</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Linda PT Joosten</dc:creator><dc:creator> Sander van Doorn</dc:creator><dc:creator> Peter M van de Ven</dc:creator><dc:creator> Bart TG Köhlen</dc:creator><dc:creator> Melchior C Nierman</dc:creator><dc:creator> Huiberdina L Koek</dc:creator><dc:creator> Martin EW Hemels</dc:creator><dc:creator> Menno V Huisman</dc:creator><dc:creator> Marieke Kruip</dc:creator><dc:creator> Laura M Faber</dc:creator><dc:creator> Nynke M Wiersma</dc:creator><dc:creator> Wim F Buding</dc:creator><dc:creator> Rob Fijnheer</dc:creator><dc:creator> Henk J Adriaansen</dc:creator><dc:creator> Kit C Roes</dc:creator><dc:creator> Arno W Hoes</dc:creator><dc:creator> Frans H Rutten</dc:creator><dc:creator> Geert-Jan Geersing</dc:creator><dc:date> 2023-08-27</dc:date><dc:source> Circulation</dc:source><dc:title> Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial</dc:title><dc:identifier> pmid:37634130</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066485</dc:identifier></item><item><title> Biventricular Arrhythmogenic Cardiomyopathy: 12-Year Natural History</title><link/> https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 27:ehad554. doi: 10.1093/eurheartj/ehad554. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634129</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad554>10.1093/eurheartj/ehad554</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37634129</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Maria Cristina Procopio</dc:creator><dc:creator> Francisco Alpedurada</dc:creator><dc:creator> Chiara Bucciarelli-Ducci</dc:creator><dc:date> 2023-08-27</dc:date><dc:source> European heart journal</dc:source><dc:title> Biventricular Arrhythmogenic Cardiomyopathy: 12-Year Natural History</dc:title><dc:identifier> pmid:37634129</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad554</dc:identifier></item><item><title> Optical Coherence Tomography-Guided or Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> Background: Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared to angiography-guided PCI. However, comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown. Methods: In this prospective, multicenter, open-label, pragmatic trial, we randomly assigned 2008 patients with significant coronary-artery lesions undergoing PCI... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066429. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared to angiography-guided PCI. However, comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown. <b>Methods:</b> In this prospective, multicenter, open-label, pragmatic trial, we randomly assigned 2008 patients with significant coronary-artery lesions undergoing PCI in a 1:1 ratio to undergo either an OCT-guided or IVUS-guided PCI. The primary end point was a composite of death from cardiac causes, target-vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year, which was powered for noninferiority of the OCT group as compared with the IVUS group. Safety outcomes were also assessed. <b>Results:</b> At 1 year, primary end-point events occurred in 25 of 1005 patients (Kaplan-Meier estimate, 2.5%) in the OCT group and in 31 of 1003 patients (Kaplan-Meier estimate, 3.1%) in the IVUS group (absolute difference, -0.6 percentage points; upper boundary of one-sided 97.5% confidence interval, 0.97 percentage points; P&lt;0.001 for noninferiority). The incidence of contrast-induced nephropathy was similar (14 patients [1.4%] in the OCT group vs. 15 patients [1.5%] in the IVUS group, P=0.85). The incidence of major procedural complications was lower in the OCT group than in the IVUS group (22 [2.2%] vs. 37 [3.7%], P=0.047), although imaging procedure-related complications were not observed. <b>Conclusions:</b> In patients with significant coronary-artery lesions, OCT-guided PCI was noninferior to IVUS-guided PCI with respect to the incidence of a composite of death from cardiac causes, target-vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year. The selected study population and lower than expected event rates should be considered in interpreting the trial.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37634092</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066429>10.1161/CIRCULATIONAHA.123.066429</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37634092</guid><pubDate> Sun, 27 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Do-Yoon Kang</dc:creator><dc:creator> Jung-Min Ahn</dc:creator><dc:creator> Sung-Cheol Yun</dc:creator><dc:creator> Seung Ho Hur</dc:creator><dc:creator> Yun-Kyeong Cho</dc:creator><dc:creator> Cheol Hyun Lee</dc:creator><dc:creator> Soon Jun Hong</dc:creator><dc:creator> Subin Lim</dc:creator><dc:creator> Sang-Wook Kim</dc:creator><dc:creator> Hoyoun Won</dc:creator><dc:creator> Jun-Hyok Oh</dc:creator><dc:creator> Jeong Cheon Choe</dc:creator><dc:creator> Young Joon Hong</dc:creator><dc:creator> Yong-Hoon Yoon</dc:creator><dc:creator> Hoyun Kim</dc:creator><dc:creator> Yeonwoo Choi</dc:creator><dc:creator> Jinho Lee</dc:creator><dc:creator> Young Won Yoon</dc:creator><dc:creator> Soo-Joong Kim</dc:creator><dc:creator> Jang Ho Bae</dc:creator><dc:creator> Duk-Woo Park</dc:creator><dc:creator> Seung-Jung Park</dc:creator><dc:creator> OCTIVUS Investigators</dc:creator><dc:date> 2023-08-27</dc:date><dc:source> Circulation</dc:source><dc:title> Optical Coherence Tomography-Guided or Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial</dc:title><dc:identifier> pmid:37634092</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066429</dc:identifier></item><item><title> Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> Thrombopoietin (THPO or TPO) is an essential cytokine for hematopoietic stem cell (HSC) maintenance and megakaryocyte differentiation. Here, we report the 3.4 Å resolution cryoelectron microscopy structure of the extracellular TPO-TPO receptor (TpoR or MPL) signaling complex, revealing the basis for homodimeric MPL activation and providing a structural rationalization for genetic loss-of-function thrombocytopenia mutations. The structure guided the engineering of TPO variants (TPO^(mod)) with a... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 22:S0092-8674(23)00852-8. doi: 10.1016/j.cell.2023.07.037. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Thrombopoietin (THPO or TPO) is an essential cytokine for hematopoietic stem cell (HSC) maintenance and megakaryocyte differentiation. Here, we report the 3.4 Å resolution cryoelectron microscopy structure of the extracellular TPO-TPO receptor (TpoR or MPL) signaling complex, revealing the basis for homodimeric MPL activation and providing a structural rationalization for genetic loss-of-function thrombocytopenia mutations. The structure guided the engineering of TPO variants (TPO <sup>mod</sup> ) with a spectrum of signaling activities, from neutral antagonists to partial- and super-agonists. Partial agonist TPO <sup>mod</sup> decoupled JAK/STAT from ERK/AKT/CREB activation, driving a bias for megakaryopoiesis and platelet production without causing significant HSC expansion in mice and showing superior maintenance of human HSCs in vitro. These data demonstrate the functional uncoupling of the two primary roles of TPO, highlighting the potential utility of TPO <sup>mod</sup> in hematology research and clinical HSC transplantation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37633268</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.037>10.1016/j.cell.2023.07.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37633268</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Naotaka Tsutsumi</dc:creator><dc:creator> Zahra Masoumi</dc:creator><dc:creator> Sophie C James</dc:creator><dc:creator> Julie A Tucker</dc:creator><dc:creator> Hauke Winkelmann</dc:creator><dc:creator> William Grey</dc:creator><dc:creator> Lora K Picton</dc:creator><dc:creator> Lucie Moss</dc:creator><dc:creator> Steven C Wilson</dc:creator><dc:creator> Nathanael A Caveney</dc:creator><dc:creator> Kevin M Jude</dc:creator><dc:creator> Cornelius Gati</dc:creator><dc:creator> Jacob Piehler</dc:creator><dc:creator> Ian S Hitchcock</dc:creator><dc:creator> K Christopher Garcia</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> Cell</dc:source><dc:title> Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis</dc:title><dc:identifier> pmid:37633268</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.037</dc:identifier></item><item><title> PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development</title><link/> https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> Selective clearance of organelles, including endoplasmic reticulum (ER) and mitochondria, by autophagy plays an important role in cell health. Here, we describe a developmentally programmed selective ER clearance by autophagy. We show that Parkinson&#39;s disease-associated PINK1, as well as Atl, Rtnl1, and Trp1 receptors, regulate ER clearance by autophagy. The E3 ubiquitin ligase Parkin functions downstream of PINK1 and is required for mitochondrial clearance while having the opposite function in... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 21:S0092-8674(23)00862-0. doi: 10.1016/j.cell.2023.08.008. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Selective clearance of organelles, including endoplasmic reticulum (ER) and mitochondria, by autophagy plays an important role in cell health. Here, we describe a developmentally programmed selective ER clearance by autophagy. We show that Parkinson&#39;s disease-associated PINK1, as well as Atl, Rtnl1, and Trp1 receptors, regulate ER clearance by autophagy. The E3 ubiquitin ligase Parkin functions downstream of PINK1 and is required for mitochondrial clearance while having the opposite function in ER clearance. By contrast, Keap1 and the E3 ubiquitin ligase Cullin3 function downstream of PINK1 to regulate ER clearance by influencing Rtnl1 and Atl. PINK1 regulates a change in Keap1 localization and Keap1-dependent ubiquitylation of the ER-phagy receptor Rtnl1 to facilitate ER clearance. Thus, PINK1 regulates the selective clearance of ER and mitochondria by influencing the balance of Keap1- and Parkin-dependent ubiquitylation of substrates that determine which organelle is removed by autophagy.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37633267</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.008>10.1016/j.cell.2023.08.008</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37633267</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Ruoxi Wang</dc:creator><dc:creator> Tina M Fortier</dc:creator><dc:creator> Fei Chai</dc:creator><dc:creator> Guangyan Miao</dc:creator><dc:creator> James L Shen</dc:creator><dc:creator> Lucas J Restrepo</dc:creator><dc:creator> Jeromy J DiGiacomo</dc:creator><dc:creator> Panagiotis D Velentzas</dc:creator><dc:creator> Eric H Baehrecke</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> Cell</dc:source><dc:title> PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development</dc:title><dc:identifier> pmid:37633267</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.008</dc:identifier></item><item><title> Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad568. doi: 10.1093/eurheartj/ehad568. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37632844</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad568>10.1093/eurheartj/ehad568</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632844</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Janine Pöss</dc:creator><dc:creator> Petra Büttner</dc:creator><dc:creator> Holger Thiele</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</dc:title><dc:identifier> pmid:37632844</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad568</dc:identifier></item><item><title> Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad506. doi: 10.1093/eurheartj/ehad506. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37632758</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad506>10.1093/eurheartj/ehad506</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632758</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Colin Baigent</dc:creator><dc:creator> Rafael Sádaba</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</dc:title><dc:identifier> pmid:37632758</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad506</dc:identifier></item><item><title> 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad476. doi: 10.1093/eurheartj/ehad476. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous guideline. The TF was asked to review all new relevant data since the 2018 guidelines including updated aggregated data from the four randomized trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary artery bypass grafting (CABG) in patients with LM disease. This document represents a summary of the work of the TF; suggested updated recommendations for the choice of revascularization modality in patients undergoing myocardial revascularization for LM disease are included. In stable patients with an indication for revascularization for LM disease, with coronary anatomy suitable for both procedures and a low predicted surgical mortality, the TF concludes that both treatment options are clinically reasonable based on patient preference, available expertise, and local operator volumes. The suggested recommendations for revascularization with CABG are Class I, Level of Evidence A. The recommendations for PCI are Class IIa, Level of Evidence A. The TF recognized several important gaps in knowledge related to revascularization in patients with LM disease and recognizes that aggregated data from the four randomized trials were still only large enough to exclude large differences in mortality.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37632756</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad476>10.1093/eurheartj/ehad476</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632756</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Robert A Byrne</dc:creator><dc:creator> Stephen Fremes</dc:creator><dc:creator> Davide Capodanno</dc:creator><dc:creator> Martin Czerny</dc:creator><dc:creator> Torsten Doenst</dc:creator><dc:creator> Jonathan R Emberson</dc:creator><dc:creator> Volkmar Falk</dc:creator><dc:creator> Mario Gaudino</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:creator> Roxana Mehran</dc:creator><dc:creator> Milan Milojevic</dc:creator><dc:creator> Miguel Sousa Uva</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</dc:title><dc:identifier> pmid:37632756</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad476</dc:identifier></item><item><title> Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828121004&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad545. doi: 10.1093/eurheartj/ehad545. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Plasma cDPP3 levels were assessed at baseline and 12-24 hours after presentation in patients with ACS prospectively enrolled into the multicentre SPUM-ACS study (n = 4787). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Circulating DPP3 levels were associated with in-hospital CS when accounting for established risk factors including the ORBI risk score (per log-2 increase, hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.05-1.82, P = 0.021). High cDPP3 was as an independent predictor of mortality at 30 days (HR 1.87, 95% CI 1.36-2.58, P &lt; 0.001) and at 1 year (HR 1.61, 95% CI 1.28-2.02, P &lt; 0.001) after adjustment for established risk factors and the GRACE 2.0 score. Compared to values within the normal range, persistently elevated cDPP3 levels at 12-24 hours were associated with 13.4-fold increased 30-day mortality risk (HR 13.42, 95% CI 4.86-37.09, P &lt; 0.001) and 5.8-fold increased 1-year mortality risk (HR 5.79, 95% CI 2.70-12.42, P &lt; 0.001). Results were consistent across various patient subgroups. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828121004&v=2.17.9.post6+86293ac">37632743</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad545>10.1093/eurheartj/ehad545</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632743</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Florian A Wenzl</dc:creator><dc:creator> Francesco Bruno</dc:creator><dc:creator> Simon Kraler</dc:creator><dc:creator> Roland Klingenberg</dc:creator><dc:creator> Alexander Akhmedov</dc:creator><dc:creator> Stefano Ministrini</dc:creator><dc:creator> Karine Santos</dc:creator><dc:creator> Konstantin Godly</dc:creator><dc:creator> Julia Godly</dc:creator><dc:creator> David Niederseer</dc:creator><dc:creator> Robert Manka</dc:creator><dc:creator> Andreas Bergmann</dc:creator><dc:creator> Giovanni G Camici</dc:creator><dc:creator> Arnold von Eckardstein</dc:creator><dc:creator> Barbara Stähli</dc:creator><dc:creator> Olivier Muller</dc:creator><dc:creator> Marco Roffi</dc:creator><dc:creator> Lorenz Räber</dc:creator><dc:creator> Thomas F Lüscher</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</dc:title><dc:identifier> pmid:37632743</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad545</dc:identifier></item></channel></rss>